---
layout: default
title: Deferasirox
parent: 僅模型預測 (L5)
nav_order: 97
evidence_level: L5
indication_count: 5
---

# Deferasirox
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Deferasirox: From Chronic Iron Overload to HIV Infectious Disease

## One-Sentence Summary

Deferasirox is an oral iron chelator approved for chronic transfusional iron overload, reducing systemic iron burden in patients dependent on regular blood transfusions.
The TxGNN model predicts it may be effective for **HIV Infectious Disease**, with **0 clinical trials** and **2 publications** currently supporting this direction — both limited to mechanistic and narrative-level studies.
The biological rationale carries a critical internal paradox that must be resolved before this candidate can advance.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Chronic iron overload due to blood transfusions |
| Predicted New Indication | HIV Infectious Disease |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L4 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the regulatory or DrugBank sources queried. Based on established pharmacological knowledge, Deferasirox is an oral tridentate chelator that selectively and irreversibly binds ferric iron (Fe³⁺) with high affinity, facilitating its excretion and reducing systemic and tissue iron burden.

The mechanistic hypothesis linking Deferasirox to HIV suppression rests on a well-described dependency: HIV replication requires iron-dependent ribonucleotide reductase (RNR) for nucleotide biosynthesis. In principle, depleting the intracellular iron pool available to RNR should limit viral DNA synthesis and slow replication — a mechanism that has also been explored in other infectious diseases and hematologic malignancies.

However, the available literature introduces a critical biological paradox that fundamentally complicates this narrative. PMID 34550543 demonstrates that endolysosomal iron actively promotes HIV-1 Tat protein oligomerization, and this oligomerization **suppresses** LTR transactivation and viral transcription. This means that chelating endolysosomal iron could paradoxically disrupt a naturally occurring host-defense mechanism, potentially shifting the balance toward enhanced viral gene expression. The net directional effect of systemic iron chelation on HIV replication is therefore bidirectionally uncertain and cannot be predicted from existing data alone. In vitro experiments specifically designed to assess net viral output under deferasirox exposure are needed before this candidate can be meaningfully evaluated.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|-------------|
| [34550543](https://pubmed.ncbi.nlm.nih.gov/34550543/) | 2021 | Basic Mechanism Study (in vitro) | Journal of Neurovirology | Endolysosomal iron promotes HIV-1 Tat oligomerization, suppressing LTR transactivation — suggests iron chelation may paradoxically relieve this natural viral suppression mechanism; direct net effect on HIV replication unresolved |
| [16529348](https://pubmed.ncbi.nlm.nih.gov/16529348/) | 2006 | Drug Launch Review | Journal of the American Pharmacists Association | Narrative overview of deferasirox at market launch; no HIV-specific efficacy or mechanistic data provided |

---

## Philippines Market Information

Currently no Philippines regulatory registration records for Deferasirox.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Other Notable Predictions

While this report focuses on the top-ranked prediction (HIV, Rank 1), the second-ranked indication — **chronic hepatitis C virus infection** (TxGNN score 99.39%, L4 evidence) — carries a substantially stronger and more internally consistent biological rationale. In transfusion-dependent populations (e.g., β-thalassemia major), hepatic iron overload is a well-documented co-morbidity that accelerates HCV-associated fibrosis via Fenton reaction-driven oxidative stress and impairs interferon signaling. Three publications support this mechanistic pathway (PMIDs [28378040](https://pubmed.ncbi.nlm.nih.gov/28378040/), [18647144](https://pubmed.ncbi.nlm.nih.gov/18647144/), [22515110](https://pubmed.ncbi.nlm.nih.gov/22515110/)). This indication may represent a more actionable near-term research question, particularly in populations where iron overload and HCV co-exist.

Predictions ranked 3–5 (rare neurodevelopmental disorder, obsolete familial combined hyperlipidemia, dermatofibrosarcoma protuberans) each carry L5 evidence with no supporting studies, and are currently assessed as **Hold**.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The mechanistic basis for deferasirox in HIV is not only unsupported by any clinical evidence, but is actively complicated by an in-vitro finding suggesting iron chelation may paradoxically disrupt a natural host-defense mechanism against viral transcription. At this stage, the direction of biological effect is unresolved, making further development premature and scientifically unjustifiable without foundational in vitro data.

**To proceed, the following is needed:**
- Controlled in vitro experiments measuring net HIV replication output (viral RNA, p24 antigen) under deferasirox exposure across a range of iron concentrations, to determine whether the RNR-inhibitory effect or the endolysosomal Tat-stabilization disruption dominates
- Full mechanism of action data from DrugBank or manufacturer package insert
- Philippines (FDA) package insert retrieval to populate key warnings, contraindications, and safety monitoring requirements
- If the in vitro paradox resolves in favor of suppression, design a dose-ranging study in a relevant HIV cell model (e.g., primary CD4⁺ T cells or macrophages) prior to any clinical planning
- Consider parallel prioritization of the HCV-in-thalassemia indication (Rank 2), which has a more coherent and unidirectional mechanistic rationale
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

